Long-term safety and efficacy of CM512 for atopic dermatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, multicenter extension in which people who completed a parent CM512 trial continue to receive CM512 and are followed over a longer period. Participants will attend regular clinic visits for safety checks, monitoring of adverse events, and clinical assessments of their skin and symptoms. The study enrolls only those who completed the week 18 visit in CM512-101102 or the end-of-study visit in CM512-100001. Data collected will focus on long-term tolerability and maintenance of any clinical benefit seen in the parent studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
* Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.

Exclusion Criteria:

* Not enough washing-out period for previous therapy.
* Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Jianzhong Zhang — Peking University People's Hospital
• Study coordinator: Qian Jia
• Email: qianjia@keymedbio.com
• Phone: +86-028-88610620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• LT-002-158 tablets for moderate-to-severe atopic dermatitis in adults

  This study tests LT-002-158 vs placebo to see if it helps adults with moderate-to-severe atopic dermatitis.

  Recruiting Phase 2 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Hangzhou, Zhejiang · NCT07895615

• PRA-216 for moderate to severe atopic dermatitis: safety and how it works in the body

  This study tests PRA-216 versus placebo to see if it is safe and helps people with moderate to severe atopic dermatitis.

  Recruiting at 6 sites Phase 2 Prana Therapies Inc · Botany, New South Wales and 8 other locations · NCT07810777

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• Global Health Look at Atopic Dermatitis

  A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.

  Recruiting University of Zurich · Zurich · NCT07659756

• Stapokibart Injection for atopic dermatitis in adults

  This study tests Stapokibart Injection in adults with atopic dermatitis to see how safe it is and whether it helps.

  Recruiting Chengdu Kangnuoxing Biopharma,Inc. · Beijing, Beijing Municipality · NCT07544862

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.